The €32.6 million ($34 million) seed round was co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, with additional backing from Savanne Life Sciences. This funding will fuel GemmaBio's operational expansion and innovative gene therapy programs.

"We are delighted by the enthusiastic support from our engaged and high-quality partners, who share our vision for the future of gene therapy," commented Jim Wilson, President and CEO of GemmaBio. "Their involvement comes at a pivotal moment in the industry, and together, we are committed to expanding and speeding access to affordable gene therapies for the patients who need them most."

GemmaBio is at the forefront of advancing gene therapy research, with a focus on accelerating the development and delivery of life-changing therapies to patients worldwide.

Since its launch on October 1, 2024, GemmaBio has initiated several active programs, including a recently announced collaboration with Fiocruz, the primary supplier of immunobiologics, biopharmaceuticals, and diagnostics to the Brazilian Ministry of Health.